IL2 and graft versus host disease: Administration of low-dose IL-2, an essential cytokine for the maintenance and proliferation of Tregs, specifically expands Tregs in vivo (23) and is a promising approach for treating autoimmune diseases and graft versus host disease (GVHD) (24, 25).